Thousands of breast cancer patients in the UK could be spared from unnecessary chemotherapy thanks to a pioneering gene test developed by researchers at the University of Warwick. The innovative test aims to more accurately predict which patients will benefit from chemotherapy, potentially reducing exposure to treatments with significant side effects.
The focus of the research is on a specific gene, FBP1, which has been identified as a key indicator of how a tumour might respond to chemotherapy. By analysing the presence and activity of this gene, clinicians could gain a clearer understanding of a patient's prognosis and the likelihood of success with various treatment pathways. This development is particularly relevant for patients with 'ER-positive, HER2-negative' breast cancer, a subtype that represents around 70% of all breast cancer diagnoses in the UK.
According to the University of Warwick, early findings suggest that this gene test could prevent up to 10,000 breast cancer patients in the UK from undergoing chemotherapy that may not be effective for them. Chemotherapy, while life-saving for many, carries a range of challenging side effects, including severe fatigue, nausea, hair loss, and an increased susceptibility to infections, significantly impacting a patient's quality of life during treatment.
Currently, treatment decisions for breast cancer often involve a complex assessment based on tumour size, grade, and lymph node involvement. While existing genomic tests are available, this new research offers a more targeted approach to refine treatment stratification. The ability to distinguish between patients who will and will not benefit from chemotherapy represents a significant step forward in personalised medicine, ensuring that treatments are as effective and as least burdensome as possible.
The research team at the University of Warwick is now planning further clinical trials to robustly validate the test's efficacy and pave the way for its potential adoption within the NHS. If successful, this could revolutionise how breast cancer is treated, leading to better patient outcomes and a more efficient allocation of healthcare resources. The long-term goal is to integrate this test into routine clinical practice, offering a more precise and humane approach to cancer care.